RBC Capital Markets set a $58.00 price objective on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in a research report report published on Monday. The brokerage currently has a a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Royal Bank Of Canada dropped their price objective on Teva Pharmaceutical Industries from $71.00 to $58.00 and set an outperform rating on the stock in a research report on Monday. Barclays PLC initiated coverage on Teva Pharmaceutical Industries in a research note on Monday. They issued an equal weight rating and a $46.00 price target on the stock. Bank of America Corp. lowered Teva Pharmaceutical Industries from a buy rating to a neutral rating and set a $48.00 price target on the stock. in a research note on Monday, November 7th. HSBC lowered Teva Pharmaceutical Industries from a buy rating to a hold rating and lifted their price target for the stock from $44.00 to $66.00 in a research note on Friday, November 4th. Finally, Credit Suisse Group AG raised Teva Pharmaceutical Industries from a neutral rating to an outperform rating and lowered their price target for the stock from $59.00 to $52.00 in a research note on Monday, October 31st. They noted that the move was a valuation call. Thirteen analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has an average rating of Buy and a consensus target price of $60.00.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 38.07 on Monday. The stock has a market capitalization of $34.80 billion, a P/E ratio of 25.43 and a beta of 0.73. The company has a 50-day moving average of $42.97 and a 200-day moving average of $49.87. Teva Pharmaceutical Industries has a 52 week low of $37.25 and a 52 week high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.02. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The company had revenue of $5.56 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter last year, the company earned $1.35 earnings per share. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. On average, analysts anticipate that Teva Pharmaceutical Industries will post $5.16 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 20th. Shareholders of record on Monday, December 5th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.57%. Teva Pharmaceutical Industries’s dividend payout ratio is presently 58.39%.

Hedge funds and other institutional investors have recently modified their holdings of the company. Sharkey Howes & Javer boosted its position in shares of Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock worth $101,000 after buying an additional 358 shares in the last quarter. Hudock Capital Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock worth $103,000 after buying an additional 564 shares in the last quarter. Washington Trust Bank boosted its position in shares of Teva Pharmaceutical Industries by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock worth $103,000 after buying an additional 58 shares in the last quarter. WFG Advisors LP boosted its position in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock worth $104,000 after buying an additional 256 shares in the last quarter. Finally, Kistler Tiffany Companies LLC boosted its position in shares of Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock worth $107,000 after buying an additional 64 shares in the last quarter. Institutional investors own 63.00% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.